 |
 Video: What is a Stock Split?
|
|
|
| Astria Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Co.'s primary product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema, a rare, debilitating and potentially life-threatening disease. STAR-0215 is in preclinical development. According to our Astria Therapeutics stock split history records, Astria Therapeutics has had 0 splits. | |
|
Astria Therapeutics (ATXS) has 0 splits in our Astria Therapeutics stock split history database.
Looking at the Astria Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Astria Therapeutics shares, starting with a $10,000 purchase of ATXS, presented on a split-history-adjusted basis factoring in the complete Astria Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
06/26/2015 |
|
| End date: |
09/22/2023 |
|
| Start price/share: |
$13.47 |
|
| End price/share: |
$6.99 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-48.11% |
|
| Average Annual Total Return: |
-7.65% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$5,187.68 |
|
| Years: |
8.25 |
|
|
|
|
|
